RPS12

Across TCGA pan-cancer cohorts, RPS12 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RPS12 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPS12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPS12 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where RPS12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.605	0.885	<.001	36	view →
LUAD	DFS	Median	All	0.989	0.816	.012	13	view →
HNSC	DFS	Median	III,IV	0.885	0.681	.012	8	view →
PDAC	OS	Quartile	All	0.513	0.303	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RPS12–CCRCC (DFS)

Open the CCRCC breakdown →